Inventiva (NASDAQ:IVA - Get Free Report) is projected to announce its Q2 2025 results before the market opens on Thursday, September 25th. Analysts expect the company to announce earnings of ($0.41) per share for the quarter. Investors can check the company's upcoming Q2 2025 earningsummary page for the latest details on the call scheduled for Monday, September 29, 2025 at 11:40 AM ET.
Inventiva Stock Performance
NASDAQ:IVA traded up $0.23 during trading hours on Friday, reaching $5.65. 63,054 shares of the company were exchanged, compared to its average volume of 76,192. Inventiva has a twelve month low of $1.53 and a twelve month high of $6.50. The stock's 50-day moving average is $4.36 and its 200-day moving average is $3.65.
Wall Street Analysts Forecast Growth
Several research analysts have weighed in on IVA shares. HC Wainwright started coverage on shares of Inventiva in a research note on Wednesday, September 3rd. They set a "buy" rating and a $20.00 target price for the company. Piper Sandler assumed coverage on shares of Inventiva in a research note on Wednesday, August 27th. They set an "overweight" rating and a $26.00 target price for the company. Finally, Guggenheim increased their price target on shares of Inventiva from $9.00 to $13.00 and gave the stock a "buy" rating in a research report on Tuesday, September 2nd. Five research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the company's stock. Based on data from MarketBeat.com, Inventiva currently has a consensus rating of "Moderate Buy" and an average price target of $14.83.
Check Out Our Latest Research Report on Inventiva
Hedge Funds Weigh In On Inventiva
A hedge fund recently bought a new stake in Inventiva stock. Creative Planning purchased a new position in shares of Inventiva S.A. Sponsored ADR (NASDAQ:IVA - Free Report) in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund purchased 10,000 shares of the company's stock, valued at approximately $32,000. 19.06% of the stock is owned by hedge funds and other institutional investors.
Inventiva Company Profile
(
Get Free Report)
Inventiva SA, a clinical-stage biopharmaceutical company, focuses on the development of oral small molecule therapies for the treatment of non-alcoholic steatohepatitis (NASH) and other diseases. Its lead product candidate is Lanifibranor, which is in Phase III clinical trial to treat NASH. The company also develops Odiparcil for the treatment of patients with mucopolysaccharidoses type VI.
Further Reading
Before you consider Inventiva, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Inventiva wasn't on the list.
While Inventiva currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
